Upadacitinib + Placebo

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Alopecia Areata

Conditions

Alopecia Areata

Trial Timeline

Oct 11, 2023 → Jan 1, 2028

NCT ID

NCT06012240

About Upadacitinib + Placebo

Upadacitinib + Placebo is a phase 3 stage product being developed by AbbVie for Alopecia Areata. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06012240. Target conditions include Alopecia Areata.

What happened to similar drugs?

1 of 19 similar drugs in Alopecia Areata were approved

Approved (1) Terminated (0) Active (18)

🔄CTP-543Sun PharmaceuticalPhase 3

🔄Deuruxolitinib + PlaceboSun PharmaceuticalPhase 3

✅Baricitinib 4 MG Oral TabletEli LillyApproved

🔄Baricitinib + PlaceboEli LillyPhase 3

🔄minoxidilJohnson & JohnsonPhase 3

🔄5% Minoxidil + 2% MinoxidilJohnson & JohnsonPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06118411	Phase 3	Active	Dec 19, 2023	Feb 1, 2028	Vitiligo
NCT06012240	Phase 3	Recruiting	Oct 11, 2023	Jan 1, 2028	Alopecia Areata
NCT05843643	Phase 3	Recruiting	Jul 19, 2023	Oct 1, 2027	Systemic Lupus Erythematosus
NCT05889182	Phase 3	Recruiting	Jun 21, 2023	Mar 1, 2028	Hidradenitis Suppurativa
NCT04927975	Phase 2	Completed	Jun 30, 2021	Aug 29, 2023	Non-Segmental Vitiligo
NCT04430855	Phase 2	Completed	Jul 14, 2020	Jan 25, 2022	Hidradenitis Suppurativa (HS)
NCT04169373	Phase 3	Completed	Nov 26, 2019	Feb 28, 2025	Spondyloarthritis
NCT02955212	Phase 3	Completed	Jan 3, 2018	Sep 3, 2020	Rheumatoid Arthritis (RA)
NCT03178487	Phase 2	Completed	Oct 24, 2017	Feb 17, 2022	Ankylosing Spondylitis (AS)
NCT02925117	Phase 2	Completed	Oct 25, 2016	Jan 31, 2019	Atopic Dermatitis

Competing Products

20 competing products in Alopecia Areata

See all competitors

Product	Company	Stage	Hype Score
Baricitinib	Eli Lilly	Phase 2	42
CTP-543	Sun Pharmaceutical	Phase 2/3	42
CTP-543	Sun Pharmaceutical	Phase 3	40
Deuruxolitinib + Placebo	Sun Pharmaceutical	Phase 3	47
Baricitinib + Placebo	Eli Lilly	Phase 2/3	38
Baricitinib 4 MG Oral Tablet	Eli Lilly	Approved	47
Baricitinib + Placebo	Eli Lilly	Phase 3	47
Baricitinib + Placebo	Eli Lilly	Phase 3	40
minoxidil	Johnson & Johnson	Phase 3	40
5% Minoxidil + 2% Minoxidil	Johnson & Johnson	Phase 3	40
Minoxidil + vehicle of 5% Minoxidil topical foam	Johnson & Johnson	Phase 2	35
5% Minoxidil Topical Foam + Vehicle Topical Foam	Johnson & Johnson	Phase 3	40
Upadacitinib + Upadacitinib Placebo	AbbVie	Phase 3	47
Secukinumab + Placebo	Novartis	Phase 2	27
Daxdilimab	Amgen	Phase 2	35
Ritlecitinib	Pfizer	Pre-clinical	30
LITFULO	Pfizer	Pre-clinical	30
Ritlecitinib	Pfizer	Pre-clinical	33
Ritlecitinib higher dose + Ritlecitinib lower dose + Placebo	Pfizer	Phase 3	47
Ritlecitinib	Pfizer	Pre-clinical	26